Attorney Advertising
F. Dominic Cerrito – Case List
Avanir Pharmaceuticals, Inc.
Avanir Pharmaceuticals, Inc., et al. v. Actavis South Atlantic LLC, et al. (D. Del 2011) – Nuedexta®
Avanir Pharmaceuticals, Inc., et al. v. Par Pharmaceutical, Inc., et al. (D. Del 2011) – Nuedexta®
Avanir Pharmaceuticals, Inc., et al. v. Wockhart, Ltd., et al. (D. Del 2011) – Nuedexta®
Avanir Pharmaceuticals, Inc., et al. v. Impax Laboratories, Inc. (D. Del 2011) – Nuedexta®
Bristol-Myers Squibb Company
Zenith Labs. v. Bristol-Myers Squibb Co. (D.N.J.) (Fed. Cir. 1992) - Duracef®
Bristol-Myers Squibb Co. v. Danbury Pharmaceutical (S.D.N.Y. 1991) - Buspar®
Celgene Corporation
Celgene Corp. v. Barr Laboratories, Inc., et al., (D.N.J. 2007) - Thalomid®
Celgene Corp. v. Natco Pharma Ltd., et al., (D.N.J. 2010) - Revlimid®
Esperion Therapeutics, Inc.
Talaria Theraputics, Inc. v. Esperion Theraputics, Inc. et al. (E.D. Va. 2001) - cholesterol reducing agents
Jazz Pharmaceuticals, Inc.
Jazz Pharmaceuticals, Inc. v. Roxane Laboratories, Inc. (D.N.J. 2010) - Xyrem®
King Pharmaceuticals, Inc./King Pharmaceuticals Research & Development, Inc.
King Pharmaceuticals, Inc. v. Sandoz Inc. (D.N.J. 2009) - Avinza®
King Pharmaceuticals Research & Development, Inc. v. Item Development AB, Interference No. 105,620 (2008) - Adenoscan®
quinn emanuel urquhart & sullivan, llp
Los Angeles • New York • San Francisco • Silicon Valley • Chicago • Washington, D.C. • Tokyo • London • Mannheim • Moscow • Hamburg
Prior results do not guarantee a similar outcome.
King Pharmaceuticals Research & Development, Inc. v. Anazao Health Corp. et al. (C.D. Cal. 2008) - Adenoscan®
King Pharmaceuticals, Inc. et al. v. Sandoz, Inc. (D.N.J. 2008) - Skelaxin®
King Pharmaceuticals, Inc. et al. v. Actavis, Inc. et al. (D.N.J. 2007) - Avinza®
King Pharmaceuticals and Astellas US LLC v. Sicor Inc. and Teva Pharmaceuticals USA, Inc. (D.Del. 2005) - Adenoscan®
King Pharmaceuticals, Inc. and Wyeth v. Teva Pharmaceuticals USA, Inc. (D.N.J. 2005) - Sonata®
Aventis Pharma Deutschland GmbH and King Pharmaceuticals v. Lupin Pharmaceuticals USA, Inc. (D. Md. 2005) - Altace®
King Pharmaceuticals, Inc. v. Eon Labs, Inc. (E.D.N.Y. 2005) - Skelaxin®
King Pharmaceuticals, Inc. v. Mutual Pharmaceuticals Co., Inc. (E.D. Pa. 2004) - Skelaxin®
King Pharmaceuticals, Inc. v. Barr Laboratories (S.D.N.Y. 2004) - Prefest®
Classen Immunotherapies v. King Pharmaceuticals, Inc. (D. Md. 2004) - Skelaxin®
King Pharmaceuticals, Inc. v. Biotech Pharmacy, Inc. (D. Nev. 2004) - Adenoscan®
King Pharmaceuticals, Inc. v. CorePharma, LLC (E.D.N.Y. 2003) - Skelaxin®
King Pharmaceuticals, Inc. v. Eon Labs, Inc. (E.D.N.Y. 2003) - Skelaxin®
King Pharmaceuticals, Inc. v. Mylan Labs (N.D. W.Va. 2003) - Levoxyl®
King Pharmaceuticals, Inc. v. KV Pharmaceuticals (D. Del. 2003) - Levoxyl®
King Pharmaceuticals and Aventis Deutschland GmbH v. Cobalt Pharmaceuticals (D. Mass. 2002) - Altace®
Kremers Urban Development Company, Schwarz Pharma, Inc.
In re Omeprazole Litigation, MDL Docket No. 1291 (M-21-81) (S.D.N.Y. 1999) - Prilosec® aaiPharma Inc. v. KudCo et al. (S.D.N.Y. 2002) - Prilosec®
LeaRonal, Inc.
Ishihara Chemical v. LeaRonal, Inc. (E.D.N.Y 1998.) (2d Cir. in related case) - industrial chemicals
2
Lubrizol Corporation
Exxon Co. v. Lubrizol Corp. (S.D.Tex.) (Fed. Cir. 1997) - industrial chemicals
Marion Merrell Dow/Tanabe Seiyaku Co.
Marion Merrell Dow v. Hoechst-Roussel (D.N.J. 1994) - Cardizem®
Marion Merrell Dow v. Par Pharmaceuticals (S.D.N.Y. 1995) - Seldane®
Tanabe Seiyaku Co. and Marion Merrell Dow v. Mylan Pharmaceuticals et al. (ITC.) (Fed. Cir. 1993) - Cardizem®
Tanabe Seiyaku Co. and Marion Merrell Dow v. Fermion Pharmaceuticals (ITC 1992) - Cardizem®
Tanabe Seiyaku Co. and Marion Merrell Dow v. Profarmaco (ITC 1992) - Cardizem®
Tanabe Seiyaku Co. and Marion Merrell Dow v. ABIC Pharmaceuticals (ITC 1992) - Cardizem®
Marion Merrell Dow v. Geneva Pharmaceuticals (D.Col.) - Seldane®
Merz Pharmaceutials GmbH & Co.
Forest Laboratories and Merz Pharma GmbH & Co. v. Cobalt Laboratories, Inc. (D. Del. 2008) - Namenda®
Forest Laboratories and Merz Pharma GmbH & Co. v. Lupin Pharmaceuticals, Inc. (D. Del. 2008) - Namenda®
Forest Laboratories and Merz Pharma GmbH & Co. v. Orchid Chemicals & Pharmaceuticals, Inc. (D. Del. 2008) - Namenda®
Forest Laboratories and Merz Pharma GmbH & Co. v. Teva Pharmaceuticals, Inc. (D. Del. 2008) - Namenda®
Forest Laboratories and Merz Pharma GmbH & Co. v. Upsher-Smith Laboratories, Inc. (D. Del. 2008) - Namenda®
Forest Laboratories and Merz Pharma GmbH & Co. v. Wochardt USA Inc. (D. Del. 2008) - Namenda®
Forest Laboratories and Merz Pharma GmbH & Co. v. PLIVA (D. Del. 2008) - Namenda®
Forest Laboratories and Merz Pharma GmbH & Co. v. Dr. Reddy’s Laboratories, Inc. (D. Del. 2008) - Namenda®
3
Forest Laboratories and Merz Pharma GmbH & Co. v. Genpharm Inc. (D. Del. 2008) - Namenda®
Forest Laboratories and Merz Pharma GmbH & Co. v. Interpharm Holdings, Inc. (D. Del. 2008) - Namenda®
Forest Laboratories and Merz Pharma GmbH & Co. v. Mylan Pharmaceuticals, Inc. (D. Del. 2008) - Namenda®
Forest Laboratories and Merz Pharma GmbH & Co. v. Sun India Pharmaceutical Industries Limited (D. Del. 2008) - Namenda®
Forest Laboratories and Merz Pharma GmbH & Co. v. Ranbaxy Inc. (D. Del. 2008) - Namenda®
Forest Laboratories and Merz Pharma GmbH & Co. v. Synthon Laboratories, Inc. (D. Del. 2008) - Namenda®
Forest Laboratories and Merz Pharma GmbH & Co. v. Orgenus Pharma Inc. (D. Del. 2008) - Namenda®
Forest Laboratories and Merz Pharma GmbH & Co. v. Apotex Inc. (D. Del. 2008) - Namenda®
Prometheus Laboratories, Inc.
Prometheus Laboratories, Inc. v. Roxane Laboratories, Inc.. (D.N.J 2011) - Lotronex®
Purdue Pharma L.P.
Purdue Pharma L.P. v. Faulding Pharmaceuticals (D. Del. 1999) – MS Contin®
Purdue Pharma L.P. v. Teva Pharmaceuticals Indus. Ltd. (S.D.N.Y. 2001) - Oxycontin®
Schwarz Pharma, Inc.
Schwarz Pharma, Inc. and Elan Corporation v. Mylan Pharmaceuticals, Inc. (N.D. W.Va. 2006) - Verelan®
Schwarz Pharma, Inc. v. Paddock Laboratories, Inc. (D. Minn. 2005) - Univasc®
Schwarz Pharma, Inc. and Cima Labs, Inc. v. Par Pharmaceutical Companies, Inc., et al., (D.N.J. 2006) - Niravam TM
Schwarz Pharma, Inc. and CIMA Labs, Inc. v. Actavis Group hf., et al., (D.N.J. 2007) - Niravam™
Schwarz Pharma Inc. v. Teva Pharmaceuticals (D.N.J. 2004) - Uniretic®
In re: Omeprazole (S.D.N.Y.) (Fed. Cir. 2003) - Prilosec®
4
Braintree Laboratories v. Schwarz Pharma, Inc. (D. Del. 2003) - Miralax®
Schwarz Pharma, Inc. v. Teva Pharmaceuticals (D.N.J. 2001) - Univasc®
Tanabe Seiyaku
Tanabe Seiyaku Co. v. United States International Trade Commission (Fed. Cir. 1997) - Cardizem®
Development Agreements
$100 million development agreement with Cobalt Labs for the development of a tablet formulation for Altace® (2006)
$200 million development agreement with Pain Therapeutics regarding Remoxy®, a tamper- resistant opoid product (2005)
$50 million strategic alliance with Palatin Technologies, Inc. to develop and market PT-141 for sexual dysfunction (2004)
Product Acquisitions
$800 million acquisition of Sonata® and Skelaxin® from Elan PLC (2003)
5